Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Rimmer

Showing results (1-10 of 11) with videos related to

Pageof 2
Sort By:
Best Practice & Research. Clinical Gastroenterology|December 16, 2023
Prognostic modelling in IBDPeter Rimmer, Tariq Iqbal
Gastroenterology|December 23, 2025
The Gut Microbiome at the Onset of Inflammatory Bowel Disease: A Systematic Review and Unified Bioinformatic SynthesisPeter Rimmer, Fan Zhang, Gregor Scott, et al.
Periodontology 2000|April 9, 2026
The role of neutrophils in the pathophysiology of inflammatory bowel diseasesJoao Paulo Steffens, Ekin Yay-Kus, Rafael Scaf de Molon, et al.
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
The IBD-disk accurately assesses disability and psychological burden at IBD diagnosis and predicts adverse outcomes in both UC and Crohn's disease during the first year of treatment: a prospective observational cohort studyPeter Rimmer, Viorelia Stoica, Maryam Ibrahim, et al.
Frontline Gastroenterology|October 24, 2025
Optimising triage of urgent referrals for suspected IBD: results from the Birmingham IBD inception studyPeter Rimmer, Jonathan Cheesbrough, Jane Harris, et al.
BMJ Open|January 6, 2025
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trialSarah Al-Shakhshir, Mohammed Nabil Quraishi, Benjamin Mullish, et al.
Crohn'S & Colitis 360|June 15, 2026
A multicentered retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitisAditi Kumar, Joshua Baxter, Peter Rimmer, et al.
Clinical Pharmacology and Therapeutics|February 16, 2026
Building a Robust Investigator-Initiated Platform: The I-CARE ExperienceJulien Kirchgesner, Laurent Beaugerie, Cédric Baumann, et al.
Journal of Crohn'S & Colitis|December 14, 2024
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic SignaturesMohammed Nabil Quraishi, Jonathan Cheesbrough, Peter Rimmer, et al.
Journal of Autoimmunity|March 24, 2024
A reverse translational approach reveals the protective roles of Mangifera indica in inflammatory bowel diseaseAnella Saviano, Anna Schettino, Nunzia Iaccarino, et al.
Pageof 2

Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Best Practice & Research. Clinical Gastroenterology|December 16, 2023
Prognostic modelling in IBDPeter Rimmer, Tariq Iqbal
Gastroenterology|December 23, 2025
The Gut Microbiome at the Onset of Inflammatory Bowel Disease: A Systematic Review and Unified Bioinformatic SynthesisPeter Rimmer, Fan Zhang, Gregor Scott, et al.
Periodontology 2000|April 9, 2026
The role of neutrophils in the pathophysiology of inflammatory bowel diseasesJoao Paulo Steffens, Ekin Yay-Kus, Rafael Scaf de Molon, et al.
Frontiers in Gastroenterology (Lausanne, Switzerland)|March 13, 2026
The IBD-disk accurately assesses disability and psychological burden at IBD diagnosis and predicts adverse outcomes in both UC and Crohn's disease during the first year of treatment: a prospective observational cohort studyPeter Rimmer, Viorelia Stoica, Maryam Ibrahim, et al.
Frontline Gastroenterology|October 24, 2025
Optimising triage of urgent referrals for suspected IBD: results from the Birmingham IBD inception studyPeter Rimmer, Jonathan Cheesbrough, Jane Harris, et al.
BMJ Open|January 6, 2025
FAecal micRobiota transplantation in primary sclerosinG chOlangitis (FARGO): study protocol for a randomised, multicentre, phase IIa, placebo-controlled trialSarah Al-Shakhshir, Mohammed Nabil Quraishi, Benjamin Mullish, et al.
Crohn'S & Colitis 360|June 15, 2026
A multicentered retrospective cohort study comparing JAK inhibitor therapies in moderate-to-severe ulcerative colitisAditi Kumar, Joshua Baxter, Peter Rimmer, et al.
Clinical Pharmacology and Therapeutics|February 16, 2026
Building a Robust Investigator-Initiated Platform: The I-CARE ExperienceJulien Kirchgesner, Laurent Beaugerie, Cédric Baumann, et al.
Journal of Crohn'S & Colitis|December 14, 2024
Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host-Microbiome-Metabolomic SignaturesMohammed Nabil Quraishi, Jonathan Cheesbrough, Peter Rimmer, et al.
Journal of Autoimmunity|March 24, 2024
A reverse translational approach reveals the protective roles of Mangifera indica in inflammatory bowel diseaseAnella Saviano, Anna Schettino, Nunzia Iaccarino, et al.
Pageof 2